HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Clinical trials for HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) trials appear
Sign up with your email to follow new studies for HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cancer drug BMS-986463 enters first human tests
Disease control Recruiting nowThis early-stage study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancers that have spread and cannot be removed by surgery. The main goals are to check the drug's safety and find the best dose. About 240 participants will receive the dru…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Could a common breast cancer drug keep ovarian cancer at bay?
Disease control Recruiting nowThis study tests whether adding letrozole, a hormone therapy used in breast cancer, to standard maintenance treatment can delay the return of ovarian cancer. About 540 women with estrogen-receptor-positive ovarian cancer who have completed initial surgery and chemotherapy will re…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: PHASE3 • Sponsor: Swiss GO Trial Group • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Can a Tumor's molecular profile improve ovarian cancer care?
Knowledge-focused Recruiting nowThis study is for people with advanced ovarian cancer. It tests whether using detailed information about a person's tumor can help doctors choose better treatments. The study will compare standard care to care guided by a special tumor board that reviews this extra information. T…
Matched conditions: HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC)
Phase: NA • Sponsor: Swiss GO Trial Group • Aim: Knowledge-focused
Last updated May 26, 2026 12:11 UTC